Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Practical Bayesian adaptive randomisation in clinical trials.

Peter F Thall1, J Kyle Wathen

  • 1Department of Biostatistics, Box 447, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. rex@mdanderson.org

European Journal of Cancer (Oxford, England : 1990)
|February 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BAR12: Bayesian Autoregressive Phase 1-2 Design for Cell Therapy Trials With Manufacturing Changes.

Statistics in medicine·2026
Same author

High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Precision generalized phase I-II designs.

Biometrics·2025
Same author

Practical Bayesian Guidelines for Small Randomized Oncology Trials.

Cancers·2025
Same author

Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Bayesian Safety and Futility Monitoring in Phase II Trials Using One Utility-Based Rule.

Statistics in medicine·2024
Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

European journal of cancer (Oxford, England : 1990)·2026
See all related articles

Bayesian adaptive randomization offers a compromise between standard clinical trial randomization and physician preference. This statistical method balances scientific validity with individualized patient care, as shown in a soft tissue sarcoma trial.

Area of Science:

  • Biostatistics
  • Clinical Trials
  • Medical Ethics

Background:

  • Randomization is the gold standard for clinical trial validity but can conflict with physician's perceived best practice.
  • Physician preference for a specific treatment, based on experience or data, may ethically override randomization.
  • However, a physician's preferred treatment might later be proven inferior through a randomized trial.

Purpose of the Study:

  • To review Bayesian adaptive randomization as a statistical method.
  • To present a practical compromise between conventional randomization and physician-led treatment selection.
  • To illustrate the method with a hypothetical example and a real-world clinical trial.

Main Methods:

  • Bayesian adaptive randomization is a statistical approach.

Related Experiment Videos

  • The method dynamically adjusts treatment allocation probabilities during a trial.
  • It balances the need for robust scientific evidence with ethical considerations of patient care.

    • Main Results:

    • The paper reviews the Bayesian adaptive randomization method.
    • A hypothetical example illustrates its application.
    • The method was applied to a trial of chemotherapy regimens for unresectable soft tissue sarcoma.

    Conclusions:

    • Bayesian adaptive randomization provides a flexible alternative to traditional randomization.
    • It allows for ethical considerations of physician preference while maintaining scientific rigor.
    • This method can lead to more efficient and ethically sound clinical trials.